New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis

Following four years of continuous Sotyktu treatment, clinical response was maintained in more than seven out of 10 patients for Psoriasis Area and Severity Index 75 in the POETYK PSO long-term...

Related Keywords

California ,United States ,Malta ,Alyssa Johnsen ,April Armstrong ,Los Angeles ,Bristol Myers Squibb ,Laboratory Abnormalities ,University Of California ,Program To ,Linkedin ,Youtube ,European Academy Of Dermatology ,Instagram ,Clinical Trial Program ,Exchange Commission ,Amgen Inc ,Twitter ,Bristol Myers Squibb Company Adverse Event ,Facebook ,Psoriasis Area ,Severity Index ,Global Assessment ,European Academy ,Spring Symposium ,Bristol Myers ,Myers Squibb ,Pioneering Paths Forward ,Transform Patient ,Risks Related ,Janus Kinase ,Bristol Myers Squibb Company ,Adverse Event ,Prescribing Information ,Medication Guide ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,